MedGenesis Therapeutix Inc. MedGenesis Therapeutix Inc.


News ] [ Our People ]

Our People

[ Management Team ] [ Board of Directors ]

Management Team

ErichErich Mohr, Ph.D., R.Psych., ICD.D
Chairman & Chief Executive Officer
Founder of MedGenesis Therapeutix Inc.

Dr. Mohr is the Chairman and CEO of MedGenesis Therapeutix Inc. which he founded in 2006. Dr. Mohr, a Professor of Medicine and Psychology at the University of Ottawa until 1997 has over 30 years of experience in experimental therapeutics of CNS disorders. He is credited with over 150 publications, book chapters and abstracts and has edited the Handbook of Clinical Trials: The neurobehavioral approach. Dr. Mohr has chaired and/or served on several regulatory advisory panels for the approval of new products for the treatment of neurodegenerative disease and is the former Chairman and Chief Executive Officer of CroMedica Global Inc. (which merged with PRA International in 2002 to form one of the world's leading contract research organizations) and is the current or past Chairman of several biotechnology companies. His most recent executive position was with PRA International as Chief Scientific Officer. He also served until recently as Chair of the Board of Governors of the University of Victoria. Over the course of his career, Dr. Mohr has overseen and/or participated in more than a dozen clinical development programs resulting in a number of approved drugs.


MatthiasMatthias Luz, M.D.
Chief Medical Officer

Dr. Luz earned his MD from Heidelberg University, Germany, where he also trained as an anesthesiologist and intensive care physician. After becoming board-certified, Dr. Luz joined the biopharmaceutical industry where he spent the past 25 years, acquiring extensive experience in preclinical and clinical drug development including regulatory affairs. Before joining MedGenesis in 2006 to lead all of the company's development efforts, Dr. Luz was the Vice President and Head, Global Product Development Services for PRA International. In this capacity, Dr. Luz led an accomplished team of senior physician-scientists and drug development experts involved in the design and implementation of high quality development programs from pre-IND to Phase 3 and submission. During a previous tenure at Behringwerke/Hoechst Marion Roussel/Aventis, Dr. Luz led the team that brought Refludan, the first therapeutic for heparin-induced thrombocytopenia, to market worldwide. Dr. Luz also held other senior positions at Knoll/Abbott and Cardion.


LaraLara Longpre, M.Sc., MBA
Chief Operating Officer

Ms. Longpre re-joined MedGenesis in October 2014 as Chief Operating Officer. She brings to MedGenesis more than 24 years of experience developing innovative and complex therapies, most recently as Chief Operating Officer at Jennerex Biotherapeutics. As COO, she was responsible for program management for the lead product, alliance management across 3 international collaboration partners, clinical operations for over 11 clinical trials, technical operations, regulatory affairs, and quality assurance. Prior to Jennerex, Ms. Longpre was Senior Vice-President, Clinical & Corporate Affairs at MedGenesis where she was responsible for business operations including the intellectual property portfolio, corporate files, and clinical development plans and budgets. Ms. Longpre continued to serve as a consultant to MedGenesis during her tenure at Jennerex. Ms. Longpre previously held several senior positions with PRA International/CroMedica including operations, regulatory affairs, and proposals & contracts. She holds a BA in Biology from Cornell University, an MSc from Harvard Medical School and an MBA from Queen's University.



MedGenesis Therapeutix Inc.